The clinical efficacy of immune checkpoint blockade in pancreatic cancer targeting PD-1 and CTLA-4 has been modest, despite the remarkable success of ICB in treatment of patients with other solid tumor malignancies4,38,39. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.